Article citationsMore>>

Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., et al. (2015) PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. The New England Journal of Medicine, 372, 311-319.
https://doi.org/10.1056/NEJMoa1411087

has been cited by the following article:

• TITLE: N-Myc Inhibition: Advances in Neuroblastoma Treatment

  AUTHORS: Md Kamrul Hasan

  KEYWORDS: Neuroblastoma, N-Myc, PI3K/mTOR, PARP1, PD-L1, HAUSP

  JOURNAL NAME: CellBio, Vol.6 No.3, September 30, 2017

  ABSTRACT: Neuroblastoma (NBL) is one of the most common solid tumors and around 15% of cancer mortality in children. Amplification of the N-Myc proto-oncogene is strongly correlated with advanced disease and poor clinical outcome in NBL. Recent studies described that ubiquitin-specific protease 7 (USP7; also known as HAUSP) interacts with N-Myc, induces deubiquitination and subsequent stabilization of N-Myc that in-turn potentiates N-Myc function, and treatment with the HAUSP inhibitor (P22077) blocked such effects.